These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 5023261)

  • 1. Oral menopausal therapy using 17- micronized estradiol. A preliminary study of effectiveness, tolerance and patient preference.
    Martin PL; Burnier AM; Greaney MO
    Obstet Gynecol; 1972 May; 39(5):771-4. PubMed ID: 5023261
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of oral continuous and transdermal cyclic 17-beta estradiol and norethindrone acetate replacement therapy on platelet aggregation in postmenopausal women.
    Kaplan PB; Gücer F; Sayin NC; Yüce MA; Yardim T
    J Reprod Med; 2002 Aug; 47(8):651-5. PubMed ID: 12216432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hormone replacement therapy with a transdermal estradiol gel and oral micronized progesterone. Effect on menopausal symptoms and lipid metabolism].
    Giuliani A; Concin H; Wieser F; Boritsch J; Wilfert H; Gruber D; Urdl W
    Wien Klin Wochenschr; 2000 Jul; 112(14):629-33. PubMed ID: 11008325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new long dosage oral contraceptive, 1.0 mg. norethindrone. A preliminary study.
    Milton MD; Nelson JH
    Pac Med Surg; 1967; 75(2):127-31. PubMed ID: 6039890
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg.
    Johansen OE; Qvigstad E
    Adv Ther; 2008 Jun; 25(6):525-51. PubMed ID: 18568306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of oral contraceptives on glucose tolerance.
    Boshell BR; Roddam RF; McAdams GL; Fox OJ
    J Reprod Fertil Suppl; 1968 Dec; 5():Suppl 5:77-88. PubMed ID: 5288232
    [No Abstract]   [Full Text] [Related]  

  • 7. Proceedings: Studies in the management of the climacteris.
    Moore B; Gustafson R; Studd JW
    J Obstet Gynaecol Br Commonw; 1974 Dec; 81(12):1005-6. PubMed ID: 4452919
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evaluation of norethindrone combined with mestranol (S-3800 C) as an oral contraceptive].
    Seiga K
    Iryo; 1968 Apr; 22(4):444-52. PubMed ID: 5686370
    [No Abstract]   [Full Text] [Related]  

  • 9. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol.
    Price TM; Blauer KL; Hansen M; Stanczyk F; Lobo R; Bates GW
    Obstet Gynecol; 1997 Mar; 89(3):340-5. PubMed ID: 9052581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen.
    Rozenberg S; Pornel B; Koninckx PR; Palacios S; Christiansen C
    Hum Reprod; 2009 Jul; 24(7):1739-47. PubMed ID: 19351658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women.
    Hemelaar M; Kenemans P; de Bie L; van de Weijer PH; van der Mooren MJ
    Fertil Steril; 2006 Apr; 85(4):979-88. PubMed ID: 16580384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose effects of progesterone in add-back therapy during GnRHa treatment.
    Cheung TH; Lo KW; Yim SF; Lam C; Lau E; Haines C
    J Reprod Med; 2005 Jan; 50(1):35-40. PubMed ID: 15730171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral and transdermal hormone replacement therapy on internal carotid artery pulsatility indices in postmenopausal women. A prospective, randomized, comparative study.
    Sendağ F; Terek MC; Karadadaş N; Bilgin O
    J Reprod Med; 2001 Nov; 46(11):962-8. PubMed ID: 11762152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose transdermal hormone therapy does not interfere with the blood pressure of hypertensive menopausal women: a pilot study.
    de Carvalho MN; Nobre F; Mendes MC; Dos Reis RM; Ferriani RA; Silva de Sá MF
    Blood Press Monit; 2008 Oct; 13(5):277-83. PubMed ID: 18799953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Personal experience in the management of the post-menopausal patient using sequential 11 plus 10 therapy (mestranol 30 mcg. and chlormadinone 1 mlg. plus mestranol 80 mcg)].
    González Gutiérrez JT
    Ginecol Obstet Mex; 1969 May; 24(151):531-7. PubMed ID: 4186794
    [No Abstract]   [Full Text] [Related]  

  • 19. Steroid and gonadotropin profiles in menopausal women on three different oral replacement regimens.
    Sipinen S; Lähteenmäki P
    Ann Clin Res; 1980 Dec; 12(6):282-7. PubMed ID: 6786204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.